Skip to main content
S&P 5007,811.54+0.59%DOW51,654.95+0.83%NASDAQ27,366.17+0.64%BTC$82,433.00+0.82%ETH$2,480.72+0.28%GOLD$4,220.50+1.53%OIL$91.61+0.13%
Smart Investors Daily
SID Premium
IN

NASDAQ · INAB

IN8bio, Inc.

Healthcare · Biotechnology

$1.38

Down-$0.04 (-2.90%)

Updated Oct 9, 2026, 8:30 PM

SID Score

3.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
8.02M
P/E ratio
-0.38
Dividend yield
0.00%
52-week range
$0.88 – $2.11
Volume
22.32K
Avg. volume
68.88K

Price performance · INAB

INAB price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 8, 2026

INAB closed at $1.38 after 21 trading sessions, up 25.45% for the selected period.

Last close
$1.38
Period change
+25.45%
Period low
$1.01
Period high
$1.42
Daily close
View OHLC price history
INAB OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 8, 2026$1.40$1.40$1.33$1.3822.32K
Oct 7, 2026$1.38$1.41$1.36$1.4020.69K
Oct 6, 2026$1.425$1.45$1.35$1.3945.59K
Oct 5, 2026$1.43$1.45$1.38$1.42107.13K
Oct 2, 2026$1.42$1.46$1.3421$1.4039.47K
Oct 1, 2026$1.36$1.46$1.36$1.4078.47K
Sep 30, 2026$1.31$1.3621$1.31$1.3330.3K
Sep 29, 2026$1.28$1.30$1.27$1.29562.21K
Sep 28, 2026$1.19$1.30$1.19$1.2474.35K
Sep 25, 2026$1.18$1.27$1.17$1.2067.59K
Sep 24, 2026$1.111$1.25$1.10$1.19180.13K
Sep 23, 2026$1.15$1.15$1.10$1.1022.61K
Sep 22, 2026$1.06$1.16$1.06$1.1441.93K
Sep 21, 2026$1.09$1.11$1.06$1.0613.78K
Sep 18, 2026$1.05$1.08$1.03$1.0820.31K
Sep 17, 2026$1.03$1.10$1.03$1.0748.06K
Sep 16, 2026$1.06$1.09$1.01$1.0129.39K
Sep 15, 2026$1.10$1.10$1.01$1.0570.91K
Sep 14, 2026$1.11$1.14$1.07$1.1120.09K
Sep 11, 2026$1.12$1.1299$1.06$1.0736.99K
Sep 10, 2026$1.08$1.11$1.08$1.1015.63K

Latest INAB news

The latest Smart Investors Daily articles mentioning INAB.

Stock researchCompany · Overview

INAB research

Overview

Company profile and research snapshot.

Company profile

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$4.00
Implied upside
—
Analysts
—
INAB recent ratings
DateFirmRatingTarget
Mar 13, 2026HC Wainwright & Co.Buy—
Mar 14, 2025HC Wainwright & Co.Buy—
Feb 12, 2025HC Wainwright & Co.Buy—
Feb 11, 2025Jones TradingBuy—
Nov 26, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 22, 2026

IN8bio to Present at Sidoti Small-Cap Virtual Conference

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that William Ho, Chief Executive Officer and Co-Founder, will participate in the Sidoti Small-Cap Virtual Conference, held September 23-24, 2026. Mr. Ho will participate in one-on-one meetings with investors throughout the conference and deliver a company

Yahoo · Sep 10, 2026

IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference

NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that William Ho, Chief Executive Officer and Co-Founder, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference, on Monday, September 14, 2026, in New York. Mr. Ho and members of the IN8bio management team will

Yahoo · Sep 9, 2026

IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development

Headshot Oxana Polyakova, Ph.D., Senior Vice President of Research & Development, IN8bio Renowned γδ T cell and T cell engager (TCE) expert brings two decades of drug discovery and development experience to IN8bio Appointment strengthens IN8bio’s leadership and domain expertise as they advance their novel γδ T cell engager platform NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell the

Benzinga · Aug 6, 2026

IN8bio Q2 EPS $(0.25) Beats $(0.37) Estimate

IN8bio (NASDAQ:INAB) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.37) by 32.43 percent. This is a 79.84 percent increase over losses of $(1.24) per share from the same

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By